Clinic
Saint Francis Medical Center
Saint Francis Medical Center was paid $10.98M by Medicaid between Jan 2018 and Dec 2024, across 197 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoSAINT FRANCIS MEDICAL CENTER
GRAND ISLAND, NE 68803
GRAND ISLAND, NE 68803
33aNPI1982675955assigned 01/30/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$10.98M
24GClaims294,683
24DCodes billed197
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Nebraska
Rank by total paid#4 of 35
Median peer was paid$190K
This provider vs. median58×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KUIPER, EVERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,792 | $1.91M | |
| 2019 | 44,676 | $1.73M | |
| 2020 | 41,005 | $1.43M | |
| 2021 | 56,721 | $1.69M | |
| 2022 | 66,283 | $2.12M | |
| 2023 | 28,744 | $1.25M | |
| 2024incomplete | 13,462 | $863K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 17,048 | 15,694 | $2.62M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 11,886 | 10,648 | $2.02M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.5% | 4,354 | 3,721 | $718K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.7% | 1,980 | 1,801 | $626K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.5% | 2,186 | 1,515 | $499K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 2,035 | 1,813 | $466K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.3% | 3,299 | 3,034 | $364K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.1% | 2,706 | 1,581 | $336K |
| G0378 | Hospital observation service, per hour | 2.6% | 1,879 | 1,530 | $284K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 2,855 | 2,715 | $268K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 779 | 370 | $171K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.5% | 608 | 572 | $162K |
185 more codes
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.4% | 1,488 | $154K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.3% | 2,121 | $148K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.2% | 1,910 | $129K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 6,781 | $118K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 411 | $111K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,471 | $84K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 942 | $73K |
| 80053 | Comprehensive metabolic panel | <1% | 14,312 | $70K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,457 | $69K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,198 | $68K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,061 | $67K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,323 | $59K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,381 | $54K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,318 | $51K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,678 | $46K |
| J3490 | Unclassified drugs | <1% | 22,624 | $44K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 127 | $44K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 233 | $43K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 363 | $40K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 160 | $38K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 943 | $33K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,616 | $30K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 246 | $30K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 123 | $30K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 349 | $29K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,440 | $29K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,470 | $29K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,604 | $26K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 502 | $24K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,812 | $22K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,544 | $20K |
| 80050 | General health panel | <1% | 3,270 | $20K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 204 | $20K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,005 | $20K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,291 | $19K |
| 96376 | <1% | 1,661 | $19K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,662 | $19K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 793 | $17K |
| 81001 | <1% | 7,488 | $14K | |
| 0099U | <1% | 81 | $14K | |
| 97597 | <1% | 173 | $13K | |
| 84439 | <1% | 1,305 | $13K | |
| 93971 | <1% | 90 | $12K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,396 | $12K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,730 | $12K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 379 | $12K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,884 | $12K |
| 83735 | <1% | 3,824 | $11K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,208 | $11K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 203 | $11K |
| 80061 | Lipid panel | <1% | 1,779 | $11K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 223 | $10K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 379 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,175 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 958 | $9K |
| 84484 | <1% | 3,985 | $9K | |
| 87081 | <1% | 1,360 | $8K | |
| 84703 | <1% | 1,225 | $8K | |
| 85027 | <1% | 2,242 | $8K | |
| 88304 | <1% | 242 | $8K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 26 | $7K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 10,612 | $7K |
| 85610 | <1% | 2,904 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,356 | $7K |
| 94770 | <1% | 69 | $7K | |
| 85730 | <1% | 1,783 | $7K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 19 | $6K |
| 86803 | <1% | 539 | $6K | |
| 97165 | <1% | 218 | $6K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 15 | $6K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,023 | $6K |
| 12001 | <1% | 41 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,043 | $6K |
| 83880 | <1% | 1,027 | $6K | |
| 59050 | <1% | 22 | $6K | |
| 87040 | <1% | 1,131 | $5K | |
| 86900 | <1% | 691 | $5K | |
| 74018 | <1% | 116 | $5K | |
| 83690 | <1% | 3,044 | $5K | |
| 83605 | <1% | 1,508 | $5K | |
| 86480 | <1% | 111 | $5K | |
| 70496 | <1% | 17 | $5K | |
| 87807 | <1% | 296 | $4K | |
| A9270 | Non-covered item or service | <1% | 7,921 | $4K |
| 82962 | <1% | 2,969 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,262 | $4K |
| 97161 | <1% | 299 | $4K | |
| 82728 | <1% | 506 | $4K | |
| 86140 | <1% | 970 | $4K | |
| 87420 | <1% | 407 | $4K | |
| 87186 | <1% | 965 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 29 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 717 | $3K |
| 96367 | <1% | 81 | $3K | |
| 82607 | <1% | 217 | $3K | |
| 86850 | <1% | 246 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 529 | $3K |
| 87077 | <1% | 788 | $3K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 15 | $3K |
| 94060 | <1% | 42 | $3K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 36 | $3K |
| 90715 | <1% | 112 | $3K | |
| 82550 | <1% | 615 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 426 | $3K |
| 87070 | <1% | 425 | $3K | |
| 82553 | <1% | 267 | $2K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 418 | $2K |
| 87506 | <1% | 12 | $2K | |
| 84145 | <1% | 213 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 97 | $2K |
| 83550 | <1% | 373 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 14 | $2K |
| 71250 | <1% | 27 | $2K | |
| 83540 | <1% | 440 | $2K | |
| 84702 | <1% | 232 | $2K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 778 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 361 | $2K |
| 97116 | <1% | 118 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 27 | $1K |
| 77080 | <1% | 28 | $1K | |
| 84100 | <1% | 596 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 116 | $1K |
| 73630 | <1% | 31 | $1K | |
| 87205 | <1% | 379 | $1K | |
| 76937 | <1% | 64 | $1K | |
| 73610 | <1% | 31 | $1K | |
| 86780 | <1% | 65 | $980.76 | |
| 85652 | <1% | 303 | $899.29 | |
| 94729 | <1% | 26 | $866.56 | |
| 83615 | <1% | 364 | $776.84 | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 24 | $750.72 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 17 | $737.50 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,898 | $715.65 |
| 94760 | <1% | 461 | $653.66 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 139 | $630.08 |
| 86901 | <1% | 643 | $622.23 | |
| 99152 | <1% | 97 | $523.97 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 19 | $454.26 |
| 85379 | <1% | 292 | $445.03 | |
| 87486 | <1% | 13 | $359.10 | |
| 87581 | <1% | 13 | $359.10 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 120 | $310.22 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 39 | $293.18 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,022 | $277.08 |
| 73560 | <1% | 15 | $274.87 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 360 | $254.77 |
| 88300 | <1% | 13 | $253.49 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 192 | $251.17 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 44 | $222.76 |
| 81003 | <1% | 1,021 | $196.45 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 141 | $173.41 |
| 73110 | <1% | 13 | $173.15 | |
| 90686 | <1% | 28 | $146.92 | |
| 87480 | <1% | 13 | $146.03 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 661 | $138.50 |
| 81025 | <1% | 1,497 | $91.06 | |
| 87660 | <1% | 13 | $79.73 | |
| 87510 | <1% | 13 | $79.73 | |
| 82150 | <1% | 15 | $74.42 | |
| 84132 | <1% | 28 | $68.87 | |
| 87075 | <1% | 28 | $65.33 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 19 | $60.04 |
| 87147 | <1% | 28 | $57.78 | |
| 80076 | <1% | 229 | $55.25 | |
| 82077 | <1% | 801 | $50.28 | |
| G0008 | Administration of influenza virus vaccine | <1% | 15 | $49.04 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 193 | $39.74 |
| 80143 | <1% | 188 | $37.07 | |
| 82947 | <1% | 13 | $31.61 | |
| 85014 | <1% | 13 | $24.43 | |
| 82803 | <1% | 17 | $16.27 | |
| 73130 | <1% | 13 | $16.00 | |
| 80320 | <1% | 17 | $15.95 | |
| 80179 | <1% | 150 | $9.22 | |
| 85018 | <1% | 13 | $7.38 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 365 | $3.40 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 67 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 57 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 20 | $0.00 |
| 96417 | 0% | 41 | $0.00 | |
| 73030 | 0% | 15 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 15 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 63 | $0.00 |
| 70498 | 0% | 16 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKUIPER, EVERT (CEO CHI HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.